Roche reports continued strong demand across portfolio in H1 2022
The Swiss pharmaceutical firm has just published its financial figures for the first half of 2022, noting among other things that hemophilia drug Hemlibra has performed well year to date.
by marketwire, translated by daniel pedersen
Swiss pharmaceutical group Roche experienced continued strong demand for its drugs and Covid-19 tests in the first half of the year, according to a Thursday press release announcing the company’s figures for the first six months of 2022.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Roche awarded priority review status for Genmab drug rival
For subscribers
